0001171843-22-004988.txt : 20220726 0001171843-22-004988.hdr.sgml : 20220726 20220726060022 ACCESSION NUMBER: 0001171843-22-004988 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220726 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220726 DATE AS OF CHANGE: 20220726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 221104794 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_072622.htm FORM 8-K Form 8-K
0001629137 False 0001629137 2022-07-26 2022-07-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 26, 2022

_______________________________

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3753927-4825712
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

181 Oyster Point Blvd.

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

In this report, "GBT," "Company," "we," "our," and "us" means Global Blood Therapeutics, Inc., and/or one or more of our subsidiaries, unless the context otherwise provides.

Item 8.01. Other Events.

On July 26, 2022, Global Blood Therapeutics, Inc. issued a press release titled "MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description
   
99.1 Press Release dated July 26, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
   
  
Date: July 26, 2022By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for Oxbryta® (voxelotor) for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). Voxelotor, an oral treatment taken once daily, is the first medicine authorized in Great Britain that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular basis of sickling and destruction of red blood cells in SCD.

“We welcome the MHRA’s marketing authorization of voxelotor as a new treatment option for many people in Great Britain living with sickle cell disease, a devastating life-long condition which for far too long has seen little therapeutic innovation,” said Beatriz F. Pujol, Ph.D., vice president, head of medical affairs EU & GCC at GBT. “Following this marketing authorization by the MHRA, we look forward to working with the National Institute of Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) with the goal of helping to facilitate rapid access to voxelotor for people living with sickle cell disease who may benefit from this important treatment.”

SCD affects approximately 15,000 people in the UK.1 People living with SCD experience progressive, serious complications and morbidities, including organ damage, which lead to decreased quality of life and early mortality.2 Furthermore, economic disadvantages and health inequalities experienced by many patients with SCD can have negative societal impacts in areas such as access to healthcare, education and employment.3-9

In 2021, voxelotor was the first SCD treatment to receive a Promising Innovative Medicine (PIM) designation from the MHRA, which subsequently granted the medicine a positive scientific opinion under the Early Access to Medicines Scheme (EAMS). This enabled healthcare professionals to treat selected patients with voxelotor prior to market authorization based on clinical factors to address a clear unmet medical need.

The marketing authorization by the MHRA, which follows the European Commission (EC) authorization earlier this year, is based on results demonstrating clinically meaningful and statistically significant improvements in hemoglobin (Hb) levels, accompanied by a reduction of hemolysis markers, for patients treated with voxelotor. Data from the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization) Study of 274 patients 12 years of age and older with SCD showed that, after 24 weeks of treatment, 51.1% of patients receiving voxelotor achieved a greater than 1 g/dL increase in Hb compared with 6.5% receiving placebo (p<0.001), with significant improvements in markers of hemolysis in indirect bilirubin and reticulocyte percentage.10 In the HOPE Study, the most common adverse reactions occurring in ≥10% of patients treated with Oxbryta with a difference of >3% compared to placebo were headache (26% vs. 22%), diarrhea (20% vs. 10%), abdominal pain (19% vs. 13%), nausea (17% vs. 10%), fatigue (14% vs. 10%), rash (14% vs. 10%) and pyrexia (12% vs. 7%).10 Results from the HOPE Study were published in June 2019 in The New England Journal of Medicine and the analysis of the complete data from the HOPE Study was published in The Lancet Haematology in April 2021.

The EC decision, which was granted in February 2022, provides marketing authorization in all EU member states, as well as the additional member states of the European Economic Area, including Iceland, Liechtenstein and Norway. The MHRA grants marketing authorization in Great Britain.

About Sickle Cell Disease 
It is estimated that more than 100,000 people in the United States,11 52,000 people in Europe,12 up to 100,000 people in Brazil,13 and millions of people throughout the world have sickle cell disease (SCD).11 SCD occurs particularly among those whose ancestors are from sub-Saharan Africa, though it also occurs in people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.11 SCD is a lifelong inherited blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.14 Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. When sickle hemoglobin becomes deoxygenated, it polymerizes to form rods, which deforms the red blood cells into sickled – crescent-shaped, rigid – cells.2,14,15 The recurrent sickling process causes destruction of the red blood cells, hemolysis and anemia (low hemoglobin due to red blood cell destruction), which drives vascular inflammation contributing to blockages in capillaries and small blood vessels (vaso-occlusion) that impede the flow of blood and oxygen delivery throughout the body. Episodes of painful vascular occlusions are commonly referred to as vaso-occlusive crises (VOCs). The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.2,15-18 Complications of SCD begin in early childhood and can include neurocognitive impairment, acute chest syndrome, and silent and overt stroke, among other serious issues.19 Early intervention and treatment of SCD have shown potential to modify the course of this disease, reduce symptoms and events, prevent long-term organ damage, and extend life expectancy.2

About Oxbryta® (voxelotor)
Voxelotor is an oral, once-daily therapy for patients with sickle cell disease (SCD). Voxelotor works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, voxelotor inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells leading to hemolysis and anemia, which are primary pathologies faced by every single person living with SCD. Through addressing hemolysis and anemia and improving oxygen delivery throughout the body, GBT believes that voxelotor has the potential to modify the course of SCD.

In November 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval for voxelotor tablets, under the brand name Oxbryta®, for the treatment of SCD in adults and children 12 years of age and older, and in December 2021, the FDA expanded the approved use of Oxbryta for the treatment of SCD in patients 4 years of age and older in the United States.9 As a condition of accelerated approval for patients ages 4 and older in the United States, GBT is studying Oxbryta in the HOPE-KIDS 2 Study, a post-approval confirmatory study using transcranial Doppler (TCD) flow velocity to assess the ability of the therapy to decrease stroke risk in children 2 to 14 years of age.

In recognition of the critical need for new SCD treatments, the FDA granted Oxbryta Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations for the treatment of patients with SCD. Additionally, Oxbryta received the prestigious 2021 Prix Galien USA award for “Best Biotechnology Product” from The Galien Foundation.

Oxbryta has been granted Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), Oxbryta was designated by the European Commission (EC) as an orphan medicinal product for the treatment of patients with SCD, and Oxbryta was granted Promising Innovative Medicine (PIM) designation in the United Kingdom from the Medicines and Healthcare products Regulatory Agency (MHRA). In February 2022, the European Commission (EC) granted Marketing Authorization for Oxbryta for the treatment of hemolytic anemia due to SCD in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). In addition, Oxbryta has been approved in the United Arab Emirates (UAE) and Oman for the treatment of SCD in adults and children 12 years of age and older.

Please click here for Important Safety Information and full Prescribing Information including Patient Information for Oxbryta in the U.S.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “will,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects” and “intends,” or similar expressions. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding GBT’s priorities, dedication, commitment, focus, goals, mission, vision and positioning; safety, efficacy and mechanism of action of Oxbryta and other product characteristics; significance of reducing sickling and hemolysis and raising hemoglobin; commercialization, awareness, delivery, availability, use and commercial and medical potential of Oxbryta; significance of the marketing authorization for Oxbryta by the MHRA; working with NICE and SMC, including access to voxelotor and related timing; ongoing and planned studies, clinical trials and registries and related protocols, activities, timing and other expectations; altering the treatment, course, trajectory and care of SCD and mitigating related complications; safety, efficacy, mechanism of action, advancement and potential of GBT’s drug candidates and pipeline; and working on new targets and discovering, developing and delivering treatments, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control, including, without limitation, risks and uncertainties relating to the COVID-19 pandemic, including the extent and duration of the impact on GBT’s business, including commercialization activities, regulatory efforts, research and development, corporate development activities and operating results, which will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease; the risks that GBT is continuing to establish its commercialization capabilities and may not be able to successfully commercialize Oxbryta; risks associated with GBT’s dependence on third parties for research, development, manufacture, distribution and commercialization activities; government and third-party payer actions, including those relating to reimbursement and pricing; risks and uncertainties relating to competitive treatments and other changes that may limit demand for Oxbryta; the risks regulatory authorities may require additional studies or data to support continued commercialization of Oxbryta; the risks that drug-related adverse events may be observed during commercialization or clinical development; data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval; compliance with obligations under the Pharmakon loan; and the timing and progress of activities under GBT’s collaboration, license and distribution agreements; along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in GBT’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
        
References

  1. Sickle Cell Society. About Sickle Cell. https://www.sicklecellsociety.org/about-sickle-cell/. Accessed May 2022.
  2. Kato GJ, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
  3. McClish DK, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50.
  4. Daniel LC, et al. Lessons Learned From a Randomized Controlled Trial of a Family-Based Intervention to Promote School Functioning for School-Age Children With Sickle Cell Disease. J Pediatr Psychol. 2015;40:1085-1094.
  5. Dampier C, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86:203-205.
  6. Dampier C, et al. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer. 2010;55:485-494.
  7. Anie KA, et al. Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK. Br J Health Psychol. 2002;7:331-344.
  8. Kambasu DM, et al. Health-related quality of life of adolescents with sickle cell disease in sub-Saharan Africa: a cross-sectional study. BMC Hematol. 2019;19:9.
  9. Lubeck D, et al. Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. JAMA Netw Open. 2019;2:e1915374.
  10. Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. A phase 3 randomized trial of Voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–19.
  11. Centers for Disease Control and Prevention. Sickle Cell Disease Data and Statistics (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 7, 2022.
  12. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125. Accessed June 12, 2020.
  13. Ministério da Saúde (Brasil), Protocolo Clínico e Diretrizes Terapêuticas da Doença Falciforme, Feb. 19, 2018.
  14. National Heart, Lung, and Blood Institute. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed February 23, 2022.
  15. Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
  16. Kato GJ, et al. J Clin Invest. 2017;127(3):750-760. 
  17. Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
  18. Nader E, et al. Front Immunol. 2020 Mar 13;11:454.
  19. Kanter J, et al. Blood Rev. 2013 Nov;27(6):279-87.

Contact: 

Steven Immergut (media)
+1 650 410 3258
simmergut@gbt.com

Claudia Nabaie (media Europe)
+41 79 906 5814
cnabaie@gbt.com

Courtney Roberts (investors)
+1 650 351 7881
croberts@gbt.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jul. 26, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 26, 2022
Entity File Number 001-37539
Entity Registrant Name Global Blood Therapeutics, Inc.
Entity Central Index Key 0001629137
Entity Tax Identification Number 27-4825712
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 181 Oyster Point Blvd.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 741-7700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_072622_htm.xml IDEA: XBRL DOCUMENT 0001629137 2022-07-26 2022-07-26 iso4217:USD shares iso4217:USD shares 0001629137 false 8-K 2022-07-26 Global Blood Therapeutics, Inc. DE 001-37539 27-4825712 181 Oyster Point Blvd. South San Francisco CA 94080 650 741-7700 false false false false Common Stock, par value $0.001 per share GBT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_072622.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_072622.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_072622.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_072622.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_072622.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-004988-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-004988-xbrl.zip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